Advances in Therapy

, Volume 35, Issue 4, pp 457–466 | Cite as

Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail

  • Richard Soper
  • Sireesh Appajosyula
  • Christina Deximo
Original Research

Abstract

Introduction

A large, statewide, fee-for-service Medicaid plan recently (October 2015) executed a complete switch from sublingual buprenorphine–naloxone [(SLBN), Suboxone®] to buccal buprenorphine–naloxone [(BBN), Bunavail®] on its preferred drug formulary. This complete formulary switch provided an opportunity to assess dynamic changes in prescribing patterns, patient/physician acceptance, and indices of potential misuse/diversion.

Methods

For the period January 1, 2015 through December 31, 2016, two datasets were analyzed: prescriptions and associated costs for buprenorphine–naloxone (BN) products and urine toxicology test results for patients in the Medicaid plan. The dataset comprised 1370 unique providers ordering 643,225 prescriptions for opioid addiction therapy. Patient and order volumes, and the rate of monthly positive laboratory values for opioid molecules and cocaine were reviewed. A targeted survey of physicians treating opioid-dependent patients with state Medicaid plan coverage was also conducted.

Results

Upon plan conversion to BBN, there was a rapid increase in monthly BBN prescriptions mirrored by a rapid decrease in SLBN prescriptions. Peak in BBN prescriptions (2633 in November 2015) was approximately 60% lower than peak in SLBN prescriptions (6531 in July 2015). An unexpected finding was a 68% reduction of the overall BN market, indicating that many BN prescriptions were abandoned. The reduction was associated with quarterly cost savings to the Medicaid plan of approximately $3.5 million. Toxicology results indicated a reduction in drug positivity (defined as positivity for cocaine and/or any opioids except buprenorphine and methadone) from 13–16% in 2015 to less than 10% in 2016. Heroin positivity decreased from approximately 9% in December 2015 to an average of less than 1% during the last quarter of 2016, while positivity for norbuprenorphine, the major metabolite of buprenorphine, showed a marked increase in 2016 vs 2015. Among physicians who responded to the targeted survey most rated BBN as more difficult to abuse or misuse than SLBN.

Conclusion

The rapid reduction in the overall BN market following a complete formulary switch from SLBN to BBN was associated with quarterly savings of $3.5 million for the state Medicaid plan. Toxicology data suggest that this cost saving was realized in the context of improved physician and patient adherence to treatment protocols. The changing market dynamics can potentially be explained by a number of contributory factors, including a reduction of diversion and illicit distribution of BN following formulary conversion. These results are considered hypothesis-generating and future research should systematically compare the propensity for diversion and abuse of BN products using various epidemiological tracking tools.

Funding

BioDelivery Sciences International, Inc.

Keywords

Buccal Buprenorphine Diversion Naloxone Opioid dependence Pain Sublingual 

Notes

Acknowledgements

Funding

Funding for this study and article processing charges were provided by BioDelivery Sciences International, Inc.

Editorial Assistance

Toxicology datasets and longitudinal data analysis were provided by hc1 Insight LLC.

Authorship

All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. All named authors met the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures

Richard Soper has been a consultant to BioDelivery Sciences, Inc. Sireesh Appajosyula has been a consultant to BioDelivery Sciences, Inc. Christina Deximo is an employee of hc1.com Inc.

Compliance with Ethical Guidelines

This article does not contain any studies with human participants or animals performed by any of the authors. On the basis of 45 Code of Federal Regulations of the HHS Protection of human subjects (Section 46.101(b)2), an IRB registration is exempt for research involving survey procedures, as long as it was obtained in a manner in which subjects can not be identified and any disclosure of the human subjects’ responses outside the research could not reasonably place the subjects at risk of criminal or civil liability or be damaging to the subjects’ financial standing, employability, or reputation. This study met all of those criteria and therefore is exempt from such registration.

Data Availability

The datasets generated and analyzed for this study are not publicly available, as they were obtained from a proprietary database via a licensing agreement.

References

  1. 1.
    Gowing L, Ali R, White JM. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. 2009;3:002025.Google Scholar
  2. 2.
    Ling W. Buprenorphine for opioid dependence. Expert Rev Neurother. 2009;9(5):609–16.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction. 2009;104(7):1193–200.CrossRefPubMedGoogle Scholar
  4. 4.
    Jones ES, Moore BA, Sindelar JL, O’Connor PG, Schottenfeld RS, Fiellin DA. Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend. 2009;99(1–3):132–40.CrossRefPubMedGoogle Scholar
  5. 5.
    Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949–58.CrossRefPubMedGoogle Scholar
  6. 6.
    Blum K, Oscar-Berman M, Femino J, et al. Withdrawal from buprenorphine/naloxone and maintenance with a natural dopaminergic agonist: a cautionary note. J Addict Res Ther. 2013.  https://doi.org/10.4172/2155-6105.1000146.Google Scholar
  7. 7.
    Makhinson M, Gomez-Makhinson J. A successful treatment of buprenorphine withdrawal with the dopamine receptor agonist pramipexole. Am J Addict. 2014;23(5):475–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Lavonas EJ, Severtson SG, Martinez EM, et al. Abuse and diversion of buprenorphine sublingual tablets and film. J Subst Abuse Treat. 2014;47(1):27–34.CrossRefPubMedGoogle Scholar
  9. 9.
    Mendelson J, Jones RT, Welm S, et al. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology. 1999;141(1):37–46.CrossRefPubMedGoogle Scholar
  10. 10.
    Stoller KB, Bigelow GE, Walsh SL, Strain EC. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology. 2001;154(3):230–42.CrossRefPubMedGoogle Scholar
  11. 11.
    Jones JD, Sullivan MA, Vosburg SK, et al. Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users. Addict Biol. 2015;20(4):784–98.CrossRefPubMedGoogle Scholar
  12. 12.
    ZUBSOLV® Full Prescribing Information (2016). Orexo US, Inc., Morristown.Google Scholar
  13. 13.
    SUBOXONE® Full Prescribing Information (2016). Indivior, Inc., Richmond.Google Scholar
  14. 14.
    BUNAVAIL® Full Prescribing Information (2016). BioDelivery Sciences International, Inc., Raleigh.Google Scholar
  15. 15.
    Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. Factors contributing to the rise of buprenorphine misuse: 2008–2013. Drug Alcohol Depend. 2014;1(142):98–104.CrossRefGoogle Scholar
  16. 16.
    Daniulaityte R, Falck R, Carlson RG. Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids. Drug Alcohol Depend. 2012;122(3):201–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011;4(1):28–41.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Bazazi AR, Yokell M, Fu JJ, Rich JD, Zaller ND. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J Addict Med. 2011;5(3):175–80.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    StreetRx.com. Street prices for buprenorphine/naloxone. Accessed May 26, 2017.Google Scholar
  20. 20.
    Cassidy TA, DasMahapatra P, Black RA, Wieman MS, Butler SF. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. Pain Med. 2014;15(3):440–51.CrossRefPubMedGoogle Scholar
  21. 21.
    Chilcoat HD, Coplan PM, Harikrishnan V, Alexander L. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin). Drug Alcohol Depend. 2016;1(165):221–8.CrossRefGoogle Scholar
  22. 22.
    Severtson SG, Ellis MS, Kurtz SP, et al. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug Alcohol Depend. 2016;1(168):219–29.CrossRefGoogle Scholar
  23. 23.
    Sullivan JG, Webster L. Novel buccal film formulation of buprenorphine–naloxone for the maintenance treatment of opioid dependence: a 12-week conversion study. Clin Ther. 2015;37(5):1064–75.CrossRefPubMedGoogle Scholar
  24. 24.
    Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. NEJM. 2015;372:241–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Butler SF, Budman SH, Licari A, et al. National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf. 2008;17(12):1142–54.CrossRefPubMedGoogle Scholar
  26. 26.
    Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Muñoz A. The development of a comprehensive risk-management program for prescription opioid analgesics: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS). Pain Med. 2007;8(2):157–70.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2018

Authors and Affiliations

  • Richard Soper
    • 1
  • Sireesh Appajosyula
    • 2
  • Christina Deximo
    • 3
  1. 1.Center for Behavioral WellnessNashvilleUSA
  2. 2.Channel BioConsulting, IncRaleighUSA
  3. 3.hc1 Insight LLCIndianapolisUSA

Personalised recommendations